Cenobamate, a New Promising Antiseizure Medication: Experimental and Clinical Aspects
Barbara Błaszczyk, Stanisław J Czuczwar, Barbara Miziak, Philippe De Deurwaerdère, Antonio Gennaro Nicotera, Gabriella Di Rosa · 2024
Read Cenobamate, a New Promising Antiseizure Medication: Experimental and Clinical Aspects by Barbara Błaszczyk, Stanisław J Czuczwar, Barbara Miziak, Philippe De Deurwaerdère, Antonio Gennaro Nicotera, Gabriella Di Rosa (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11640885.txt.
Description
Barbara Blaszczyk and co-authors review a newer drug for epilepsy in a 2024 paper. Many patients with hard-to-treat epilepsy still have seizures on current drugs. The drug cenobamate was cleared in the United States and Europe as an add-on for focal seizures. The review joins lab studies with trials in patients.
The drug works in two ways at once. It curbs a steady sodium flow that fuels firing, and it boosts a calming signal in the brain. In lab seizure models it blocked most seizure types, with one clear exception. In trials, add-on use left more patients seizure-free than other add-ons did. Side effects were on par with peer drugs. The drug also showed signs of guarding brain cells. The authors see promise for changing the course of the illness, not just its symptoms.
Catalog record
| CREATOR | Barbara Błaszczyk, Stanisław J Czuczwar, Barbara Miziak, Philippe De Deurwaerdère, Antonio Gennaro Nicotera, Gabriella Di Rosa |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |